A randomized, 4-week double-blind placebo control study on the efficacy of donepezil augmentation of lithium for treatment of acute mania
Jing Chen,1 Zheng Lu,1,2 Mingyuan Zhang,1 Jie Zhang,1 Xiaodong Ni,1 Xuefeng Jiang,1 Heding Xu,1 Anisha Heeramun-Aubeeluck,2 Qiaoyan Hu,3 Hua Jin,4 John M Davis31Shanghai Mental Health Center, Shanghai Jiaotong University School of Medicine, Shanghai, People’s Republic of China; 2Department...
Guardado en:
| Autores principales: | , , , , , , , , , , |
|---|---|
| Formato: | article |
| Lenguaje: | EN |
| Publicado: |
Dove Medical Press
2013
|
| Materias: | |
| Acceso en línea: | https://doaj.org/article/433343535ffc478693b4968f508b8397 |
| Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
| id |
oai:doaj.org-article:433343535ffc478693b4968f508b8397 |
|---|---|
| record_format |
dspace |
| spelling |
oai:doaj.org-article:433343535ffc478693b4968f508b83972021-12-02T07:45:23ZA randomized, 4-week double-blind placebo control study on the efficacy of donepezil augmentation of lithium for treatment of acute mania1176-63281178-2021https://doaj.org/article/433343535ffc478693b4968f508b83972013-06-01T00:00:00Zhttp://www.dovepress.com/a-randomized-4-week-double-blind-placebo-control-study-on-the-efficacy-a13379https://doaj.org/toc/1176-6328https://doaj.org/toc/1178-2021Jing Chen,1 Zheng Lu,1,2 Mingyuan Zhang,1 Jie Zhang,1 Xiaodong Ni,1 Xuefeng Jiang,1 Heding Xu,1 Anisha Heeramun-Aubeeluck,2 Qiaoyan Hu,3 Hua Jin,4 John M Davis31Shanghai Mental Health Center, Shanghai Jiaotong University School of Medicine, Shanghai, People’s Republic of China; 2Department of Psychiatry, Tongji Hospital of Tongji University, Shanghai, People’s Republic of China; 3University of Illinois at Chicago, Chicago, IL, USA; 4University of California at San Diego, San Diego, CA, USAIntroduction: A significant number of mania patients fail to respond to current pharmacotherapy, thereby there is need for novel augmentation strategies. The results of some early studies showed the effectiveness of cholinomimetics in the treatment of mania. One open case series suggested the efficacy of donepezil in the treatment of bipolar disorder. Our aim was to explore whether an oral cholinesterase inhibitor, donepezil, administered during a 4-week treatment period,would benefit patients with acute mania.Methods: We conducted a 4-week double-blind, placebo-controlled trial of donepezil as an adjunctive treatment to lithium in patients with acute mania. Eligible subjects were randomly assigned to receive donepezil or placebo in addition to lithium. Donepezil was started at 5 mg/day, and increased to 10 mg/day in the first week. Patients were rated with the Young Mania Rating Scale (YMRS) and Brief Psychiatric Rating Scale (BPRS) at baseline, day 1, week 1, week 2, and week 4.Results: Out of the 30 patients who were enrolled, 15 were on donepezil and 15 were on placebo. All patients completed the 4-week trial. On the first day, there was a difference of 1.97 units on the psychomotor symptoms scale of the YMRS in the donepezil group as compared to the placebo group (t = 2.39, P = 0.02). There was a difference of 0.57 units (t = 2.09, P = 0.04) in the speech item and a difference of 0.29 units in the sexual interest item (t = 2.11, P = 0.04) in the donepezil group as compared to the placebo group. The total YMRS difference on the first day approached the conventional significance level (1.97 units, t = 1.84, P = 0.07). Over the course of 4 weeks, we failed to find that donepezil produced any significant difference in the YMRS (6.71 units difference, t = −1.44, P = 0.16) or the BPRS scale (1.29 units difference, t = −0.33, P = 0.75) as compared to placebo. Ten subjects (66.67%) in both groups met the criteria for clinical response (Fisher’s exact P = 1.00). Five subjects (33.33%) in the donepezil group met the criteria for clinical remission while nine subjects (60.00%) in the placebo group met the remission criteria (Fisher’s exact P = 0.27).Conclusion: Use of the oral anticholinergic donepezil had some benefit in the augmentation of lithium treatment on the first day, but did not provide any significant benefits in the long-term.Keywords: acute mania, cholinesterase inhibitors, donepezil, lithiumChen JLu ZZhang MZhang JNi XJiang XXu HHeeramun-Aubeeluck AHu QJin HDavis JMDove Medical PressarticleNeurosciences. Biological psychiatry. NeuropsychiatryRC321-571Neurology. Diseases of the nervous systemRC346-429ENNeuropsychiatric Disease and Treatment, Vol 2013, Iss default, Pp 839-845 (2013) |
| institution |
DOAJ |
| collection |
DOAJ |
| language |
EN |
| topic |
Neurosciences. Biological psychiatry. Neuropsychiatry RC321-571 Neurology. Diseases of the nervous system RC346-429 |
| spellingShingle |
Neurosciences. Biological psychiatry. Neuropsychiatry RC321-571 Neurology. Diseases of the nervous system RC346-429 Chen J Lu Z Zhang M Zhang J Ni X Jiang X Xu H Heeramun-Aubeeluck A Hu Q Jin H Davis JM A randomized, 4-week double-blind placebo control study on the efficacy of donepezil augmentation of lithium for treatment of acute mania |
| description |
Jing Chen,1 Zheng Lu,1,2 Mingyuan Zhang,1 Jie Zhang,1 Xiaodong Ni,1 Xuefeng Jiang,1 Heding Xu,1 Anisha Heeramun-Aubeeluck,2 Qiaoyan Hu,3 Hua Jin,4 John M Davis31Shanghai Mental Health Center, Shanghai Jiaotong University School of Medicine, Shanghai, People’s Republic of China; 2Department of Psychiatry, Tongji Hospital of Tongji University, Shanghai, People’s Republic of China; 3University of Illinois at Chicago, Chicago, IL, USA; 4University of California at San Diego, San Diego, CA, USAIntroduction: A significant number of mania patients fail to respond to current pharmacotherapy, thereby there is need for novel augmentation strategies. The results of some early studies showed the effectiveness of cholinomimetics in the treatment of mania. One open case series suggested the efficacy of donepezil in the treatment of bipolar disorder. Our aim was to explore whether an oral cholinesterase inhibitor, donepezil, administered during a 4-week treatment period,would benefit patients with acute mania.Methods: We conducted a 4-week double-blind, placebo-controlled trial of donepezil as an adjunctive treatment to lithium in patients with acute mania. Eligible subjects were randomly assigned to receive donepezil or placebo in addition to lithium. Donepezil was started at 5 mg/day, and increased to 10 mg/day in the first week. Patients were rated with the Young Mania Rating Scale (YMRS) and Brief Psychiatric Rating Scale (BPRS) at baseline, day 1, week 1, week 2, and week 4.Results: Out of the 30 patients who were enrolled, 15 were on donepezil and 15 were on placebo. All patients completed the 4-week trial. On the first day, there was a difference of 1.97 units on the psychomotor symptoms scale of the YMRS in the donepezil group as compared to the placebo group (t = 2.39, P = 0.02). There was a difference of 0.57 units (t = 2.09, P = 0.04) in the speech item and a difference of 0.29 units in the sexual interest item (t = 2.11, P = 0.04) in the donepezil group as compared to the placebo group. The total YMRS difference on the first day approached the conventional significance level (1.97 units, t = 1.84, P = 0.07). Over the course of 4 weeks, we failed to find that donepezil produced any significant difference in the YMRS (6.71 units difference, t = −1.44, P = 0.16) or the BPRS scale (1.29 units difference, t = −0.33, P = 0.75) as compared to placebo. Ten subjects (66.67%) in both groups met the criteria for clinical response (Fisher’s exact P = 1.00). Five subjects (33.33%) in the donepezil group met the criteria for clinical remission while nine subjects (60.00%) in the placebo group met the remission criteria (Fisher’s exact P = 0.27).Conclusion: Use of the oral anticholinergic donepezil had some benefit in the augmentation of lithium treatment on the first day, but did not provide any significant benefits in the long-term.Keywords: acute mania, cholinesterase inhibitors, donepezil, lithium |
| format |
article |
| author |
Chen J Lu Z Zhang M Zhang J Ni X Jiang X Xu H Heeramun-Aubeeluck A Hu Q Jin H Davis JM |
| author_facet |
Chen J Lu Z Zhang M Zhang J Ni X Jiang X Xu H Heeramun-Aubeeluck A Hu Q Jin H Davis JM |
| author_sort |
Chen J |
| title |
A randomized, 4-week double-blind placebo control study on the efficacy of donepezil augmentation of lithium for treatment of acute mania |
| title_short |
A randomized, 4-week double-blind placebo control study on the efficacy of donepezil augmentation of lithium for treatment of acute mania |
| title_full |
A randomized, 4-week double-blind placebo control study on the efficacy of donepezil augmentation of lithium for treatment of acute mania |
| title_fullStr |
A randomized, 4-week double-blind placebo control study on the efficacy of donepezil augmentation of lithium for treatment of acute mania |
| title_full_unstemmed |
A randomized, 4-week double-blind placebo control study on the efficacy of donepezil augmentation of lithium for treatment of acute mania |
| title_sort |
randomized, 4-week double-blind placebo control study on the efficacy of donepezil augmentation of lithium for treatment of acute mania |
| publisher |
Dove Medical Press |
| publishDate |
2013 |
| url |
https://doaj.org/article/433343535ffc478693b4968f508b8397 |
| work_keys_str_mv |
AT chenj arandomized4weekdoubleblindplacebocontrolstudyontheefficacyofdonepezilaugmentationoflithiumfortreatmentofacutemania AT luz arandomized4weekdoubleblindplacebocontrolstudyontheefficacyofdonepezilaugmentationoflithiumfortreatmentofacutemania AT zhangm arandomized4weekdoubleblindplacebocontrolstudyontheefficacyofdonepezilaugmentationoflithiumfortreatmentofacutemania AT zhangj arandomized4weekdoubleblindplacebocontrolstudyontheefficacyofdonepezilaugmentationoflithiumfortreatmentofacutemania AT nix arandomized4weekdoubleblindplacebocontrolstudyontheefficacyofdonepezilaugmentationoflithiumfortreatmentofacutemania AT jiangx arandomized4weekdoubleblindplacebocontrolstudyontheefficacyofdonepezilaugmentationoflithiumfortreatmentofacutemania AT xuh arandomized4weekdoubleblindplacebocontrolstudyontheefficacyofdonepezilaugmentationoflithiumfortreatmentofacutemania AT heeramunaubeelucka arandomized4weekdoubleblindplacebocontrolstudyontheefficacyofdonepezilaugmentationoflithiumfortreatmentofacutemania AT huq arandomized4weekdoubleblindplacebocontrolstudyontheefficacyofdonepezilaugmentationoflithiumfortreatmentofacutemania AT jinh arandomized4weekdoubleblindplacebocontrolstudyontheefficacyofdonepezilaugmentationoflithiumfortreatmentofacutemania AT davisjm arandomized4weekdoubleblindplacebocontrolstudyontheefficacyofdonepezilaugmentationoflithiumfortreatmentofacutemania AT chenj randomized4weekdoubleblindplacebocontrolstudyontheefficacyofdonepezilaugmentationoflithiumfortreatmentofacutemania AT luz randomized4weekdoubleblindplacebocontrolstudyontheefficacyofdonepezilaugmentationoflithiumfortreatmentofacutemania AT zhangm randomized4weekdoubleblindplacebocontrolstudyontheefficacyofdonepezilaugmentationoflithiumfortreatmentofacutemania AT zhangj randomized4weekdoubleblindplacebocontrolstudyontheefficacyofdonepezilaugmentationoflithiumfortreatmentofacutemania AT nix randomized4weekdoubleblindplacebocontrolstudyontheefficacyofdonepezilaugmentationoflithiumfortreatmentofacutemania AT jiangx randomized4weekdoubleblindplacebocontrolstudyontheefficacyofdonepezilaugmentationoflithiumfortreatmentofacutemania AT xuh randomized4weekdoubleblindplacebocontrolstudyontheefficacyofdonepezilaugmentationoflithiumfortreatmentofacutemania AT heeramunaubeelucka randomized4weekdoubleblindplacebocontrolstudyontheefficacyofdonepezilaugmentationoflithiumfortreatmentofacutemania AT huq randomized4weekdoubleblindplacebocontrolstudyontheefficacyofdonepezilaugmentationoflithiumfortreatmentofacutemania AT jinh randomized4weekdoubleblindplacebocontrolstudyontheefficacyofdonepezilaugmentationoflithiumfortreatmentofacutemania AT davisjm randomized4weekdoubleblindplacebocontrolstudyontheefficacyofdonepezilaugmentationoflithiumfortreatmentofacutemania |
| _version_ |
1718399218908921856 |